Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid ß42.
Biomark Med
; 6(4): 409-17, 2012 Aug.
Article
en En
| MEDLINE
| ID: mdl-22917143
ABSTRACT
Cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) are increasingly used in clinical settings, research and drug trials. However, their broad-scale use on different technology platforms is hampered by the lack of standardization at the level of sample handling, determination of concentrations of analytes and the absence of well-defined performance criteria for in vitro diagnostic or companion diagnostic assays, which influences the apparent concentration of the analytes measured and the subsequent interpretation of the data. There is a need for harmonization of CSF AD biomarker assays that can reliably, across centers, quantitate CSF biomarkers with high analytical precision, selectivity and stability over long time periods. In this position paper, we discuss reference procedures for the measurement of CSF AD biomarkers, especially amyloid ß42 and tau. We describe possible technical approaches, focusing on a selected reaction monitoring mass spectrometry assay as a candidate reference method for quantification of CSF amyloid ß42.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Fragmentos de Péptidos
/
Proyectos de Investigación
/
Péptidos beta-Amiloides
/
Enfermedad de Alzheimer
Límite:
Humans
Idioma:
En
Revista:
Biomark Med
Asunto de la revista:
BIOQUIMICA
/
MEDICINA
Año:
2012
Tipo del documento:
Article
País de afiliación:
Suecia